Kymera Therapeutics, Inc.
KYMR
Rank in Stocks
#2214
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Share Price
$114.38
Market Cap
$9.41B
Change (1 day)
5.84%
Change (1 year)
89.06%
Country
US
Trade Kymera Therapeutics, Inc. (KYMR)
Category
Healthcare
Number of shares outstanding for Kymera Therapeutics, Inc. (KYMR)
Number of shares outstanding as of June 2026: 98.18M
According to Kymera Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 98.18M. At the end of December 2023 the company had 58.37M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Kymera Therapeutics, Inc. (KYMR) from 2018 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 98.18M | 30.83% |
| 2024 | 75.04M | 28.58% |
| 2023 | 58.37M | 8.22% |
| 2022 | 53.93M | 12.39% |
| 2021 | 47.99M | 7.70% |
| 2020 | 44.56M | 0.06% |
| 2019 | 44.53M | 0.00% |
| 2018 | 44.53M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 158.61% |
US
|
|
| 396.00M | 303.35% |
US
|
|
| 478.91M | 387.80% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -36.66% |
NL
|
